Senzime

“Another great US contract and a strong showcase of our ability to expand within IDNs. We have now delivered more than 5,000 TetraGraphs to the market, and our unique technology has rapidly emerged as a key component within IDNs and modern anesthesia practice. With unmatched clinical accuracy, strong scientific validation, and a leading reference base, I am incredibly proud of the Senzime team and how we are advancing patient safety while contributing to more cost-effective healthcare”, comments Philip Siberg, CEO of Senzime.

Senzime’s solutions are used by anesthesiologists in over 750 hospitals worldwide to enhance patient safety during and after surgery. The TetraGraph^® system uses proprietary algorithms and advanced sensors to monitor the electrical activity of patients’ muscles during surgery. This helps clinicians optimize dosing of neuromuscular blocking and reversal agents as well as help determine when it is safe to intubate patients and restore spontaneous breathing after surgery.